LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 1401 | 3008 | 4245 | 0.7108 | 0.6154 |
| SK-BR-3 | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 2976 | 4168 | 0.7140 | 0.6135 |
| SK-BR-3 | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1281 | 4168 | 0.3073 | -0.0560 |
| SK-BR-3 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1121 | 4168 | 0.2691 | -0.1322 |
| SK-BR-3 | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1041 | 4168 | 0.2494 | -0.1739 |
| SK-BR-3 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1120 | 4168 | 0.2688 | -0.1329 |
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 1401 | 1068 | 4168 | 0.2560 | -0.1601 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1437 | 4168 | 0.3450 | 0.0161 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1416 | 4168 | 0.3400 | 0.0066 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1401 | 4168 | 0.3365 | -0.0001 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1574 | 4168 | 0.3776 | 0.0762 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1550 | 4168 | 0.3716 | 0.0641 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1401 | 1223 | 4168 | 0.2935 | -0.0830 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3338 | 4168 | 0.8011 | 0.7369 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3770 | 4168 | 0.9037 | 0.8741 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4046 | 4168 | 0.9707 | 0.9623 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4113 | 4168 | 0.9868 | 0.9832 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4252 | 4168 | 1.0200 | 1.0254 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 72 | hr | 1401 | 4299 | 4168 | 1.0319 | 1.0407 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3831 | 4245 | 0.9026 | 0.8757 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3872 | 4245 | 0.9103 | 0.8833 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3707 | 4245 | 0.8730 | 0.8365 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3545 | 4245 | 0.8337 | 0.7824 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3443 | 4245 | 0.8089 | 0.7481 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 1401 | 3075 | 4245 | 0.7234 | 0.6313 |